Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Novocure Ltd Ord Sh (NVCR)

Novocure Ltd Ord Sh (NVCR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,538,495
  • Shares Outstanding, K 113,794
  • Annual Sales, $ 655,350 K
  • Annual Income, $ -136,230 K
  • EBIT $ -113 M
  • EBITDA $ -185 M
  • 60-Month Beta 0.71
  • Price/Sales 2.37
  • Price/Cash Flow N/A
  • Price/Book 4.48

Options Overview Details

View History
  • Implied Volatility 120.00% (-2.45%)
  • Historical Volatility 114.28%
  • IV Percentile 95%
  • IV Rank 73.17%
  • IV High 146.13% on 02/13/26
  • IV Low 48.72% on 06/06/25
  • Expected Move (DTE 16) 2.42 (18.21%)
  • Put/Call Vol Ratio 0.77
  • Today's Volume 830
  • Volume Avg (30-Day) 2,290
  • Put/Call OI Ratio 0.47
  • Today's Open Interest 42,409
  • Open Int (30-Day) 31,589
  • Expected Range 10.88 to 15.72

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.40
  • Number of Estimates 4
  • High Estimate -0.34
  • Low Estimate -0.49
  • Prior Year -0.31
  • Growth Rate Est. (year over year) -29.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.82 +35.44%
on 02/09/26
15.46 -13.97%
on 02/25/26
+1.46 (+12.33%)
since 02/03/26
3-Month
9.82 +35.44%
on 02/09/26
15.46 -13.97%
on 02/25/26
+1.49 (+12.62%)
since 12/03/25
52-Week
9.82 +35.44%
on 02/09/26
21.55 -38.28%
on 03/12/25
-5.11 (-27.76%)
since 03/03/25

Most Recent Stories

More News
Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer

Novocure to launch Optune Lua in Japan with national reimbursement coverage

NVCR : 13.30 (-1.63%)
Novocure to Participate in 2026 Leerink Global Healthcare Conference

Novocure (NASDAQ: NVCR) announced today that management will participate in the Leerink Global Healthcare Conference on Tuesday, March 10, 2026. Frank Leonard, Chief Executive Officer, and Christoph Brackmann,...

NVCR : 13.30 (-1.63%)
NovoCure: Q4 Earnings Snapshot

NovoCure: Q4 Earnings Snapshot

NVCR : 13.30 (-1.63%)
Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update

Full year 2025 net revenues of $655 million and fourth quarter net revenues of $174 million Optune Pax ® approved by the U.S. FDA for the...

NVCR : 13.30 (-1.63%)
Tumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer)

British Columbia becomes first Canadian province to provide coverage for TTFields therapy for eligible glioblastoma patients

NVCR : 13.30 (-1.63%)
U.S. FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer

Optune Pax concomitant with gemcitabine and nab-paclitaxel is the first treatment to be FDA approved in nearly 30 years for locally advanced pancreatic cancer Phase 3...

NVCR : 13.30 (-1.63%)
Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update

Preliminary full year 2025 net revenues of $655 million and fourth quarter net revenues of $174 million Novocure to present at the 44 th Annual...

NVCR : 13.30 (-1.63%)
Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference

Novocure (NASDAQ: NVCR) announced today that management will participate in the 44 th Annual J.P. Morgan Healthcare Conference taking place in San Francisco on January 12-15, 2026. Frank...

NVCR : 13.30 (-1.63%)
Novocure Appoints Company President Frank Leonard as Chief Executive Officer

Novocure (NASDAQ: NVCR) today announced the appointment of Frank Leonard as Chief Executive Officer (CEO), effective immediately. Mr. Leonard previously served as President of Novocure and succeeds Ashley...

NVCR : 13.30 (-1.63%)
Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference

Novocure (NASDAQ: NVCR) announced today that management will participate in the 37 th Annual Piper Sandler Healthcare Conference in New York on Tuesday, December 2, 2025. William Doyle,...

NVCR : 13.30 (-1.63%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Bearish.

See More Share

Business Summary

NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands.

See More

Key Turning Points

3rd Resistance Point 15.12
2nd Resistance Point 14.33
1st Resistance Point 13.82
Last Price 13.30
1st Support Level 12.52
2nd Support Level 11.73
3rd Support Level 11.22

See More

52-Week High 21.55
Fibonacci 61.8% 17.07
Fibonacci 50% 15.68
Fibonacci 38.2% 14.30
Last Price 13.30
52-Week Low 9.82

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar